The UK NCRI AML Working Group also addressed the issue whether molecular profiling and sequential RT-qPCR-based monitoring of MRD in patients with NPM1-mutated AML treated with intensive chemotherapy may provide prognostic information useful in routine practice [45]. The gene discussed is NPM1; the disease is acute myeloid leukemia.